Skip to content

Efficacy of ultrasound-monitored meniscal wall betamethasone infiltration on pain in relation to degenerative meniscal injury: a randomized, double-blind, placebo-controlled multicenter trial. MINUS (Meniscal INfiltration of corticosteroid guided with Ultra Sonography)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-510079-74-00
Acronym
RC31/23/0387
Enrollment
152
Registered
2024-07-19
Start date
2025-03-06
Completion date
Unknown
Last updated
2025-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

meniscal pain of degenerative origin

Brief summary

The primary endpoint is the change in meniscal pain measured using the Visual Analog Scale (VAS) between the initial visit and the 1-month follow-up visit

Detailed description

the evolution of the VAS score between the initial visit and the 3-month follow-up visit, the evolution of the score of each dimension (Pain, Symptoms, Activities of daily living, Sport and recreation function, and Knee-related qualities of life) of the algo-functional scale KOOS (appendix 1) between the initial visit and the 1-month follow-up visit, the evolution of each dimension of the algo-functional scale KOOS score between the initial visit and the 3-month follow-up visit, the occurrence of adverse events (AEs) and serious AEs (SAEs) up to 3 months of follow-up, Analgesic response is defined as a at least 50% reduction in pain (measured using the VAS scale) between the initial visit and the 1-month follow-up visit.

Interventions

DRUGCHLORHYDRATE DE LIDOCAINE RENAUDIN 10 mg/ml
DRUGsolution injectable
DRUGDIPROSTENE
DRUGsuspension injectable en seringue pré-remplie

Sponsors

Centre Hospitalier Universitaire De Toulouse
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the change in meniscal pain measured using the Visual Analog Scale (VAS) between the initial visit and the 1-month follow-up visit

Secondary

MeasureTime frame
the evolution of the VAS score between the initial visit and the 3-month follow-up visit, the evolution of the score of each dimension (Pain, Symptoms, Activities of daily living, Sport and recreation function, and Knee-related qualities of life) of the algo-functional scale KOOS (appendix 1) between the initial visit and the 1-month follow-up visit, the evolution of each dimension of the algo-functional scale KOOS score between the initial visit and the 3-month follow-up visit, the occurrence of adverse events (AEs) and serious AEs (SAEs) up to 3 months of follow-up, Analgesic response is defined as a at least 50% reduction in pain (measured using the VAS scale) between the initial visit and the 1-month follow-up visit.

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026